Aveo Investors Want Class Cert. In Kidney Cancer Drug Spat
Investors claiming Aveo Pharmaceuticals Inc. hid U.S. Food and Drug Administration concerns about its kidney cancer drug from them asked a Massachusetts federal court Thursday to certify their proposed class, calling...To view the full article, register now.
Already a subscriber? Click here to view full article